Name: Bezuclastinib in Gastrointestinal stromal tumor: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Place of product in therapy Disease description Burden of Gastrointestinal stromal tumor

Humanistic burden and health-related quality of life

5 evidence topics · 5 sources

Humanistic burden

“Severe fatigue occurs in 30% of GIST patients and in 33% of GIST patients on a TKI.” (opens the source at this quote in a new tab)

Quality of life, fear of recurrence, and adherence during imatinib treatment

“Approximately 3 out of 4 patients report high fear of cancer recurrence / progression” (opens the source at this quote in a new tab)
“Therapy adherence was high (96.1%).” (opens the source at this quote in a new tab)

Patient-reported symptoms

“Fatigue and muscle pain or cramps were reported most frequently.” (opens the source at this quote in a new tab)

Systematic review of quality of life and adverse events

“A total of 104 papers were included; 13 studies addressed HRQoL, and 96 studies investigated adverse events.” (opens the source at this quote in a new tab)

Health-state utilities from GRID

“Mean baseline utility was 0.767 (SD 0.221)” (opens the source at this quote in a new tab)
“The first post-progression health state was 0.647 (SD 0.343)” (opens the source at this quote in a new tab)